Bath & Body Works Full Year 2025 Earnings: EPS Beats Expectations

Bath & Body Works (NYSE:BBWI) Full Year 2025 Results

Key Financial Results

• Revenue: US$7.31b (down 1.6% from FY 2024).
• Net income: US$798.0m (down 9.1% from FY 2024).
• Profit margin: 11% (in line with FY 2024).
• EPS: US$3.63 (down from US$3.85 in FY 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bath & Body Works EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.8%.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$6.32b (86% of total revenue). Notably, cost of sales worth US$4.07b amounted to 56% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to US$1.43b (59% of total expenses). Explore how BBWI's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Specialty Retail industry in the US.

Performance of the American Specialty Retail industry.

The company's shares are down 9.6% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Bath & Body Works (1 is potentially serious!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.